Efficacy of Diaphragmatic Proprioceptive Neuromuscular Facilitation on Functional Capacity and Pulmonary Function in Heavy Twenties Smokers
1 other identifier
interventional
40
1 country
1
Brief Summary
Although research on the health risks of e-cigarettes is still limited, there is increasing evidence of debilitating lung disease and general immune dysfunction from e-cigarettes, leading to various infections. Moreover, there are concerns that e-cigarettes can cause general impairment in life functions and more importantly lung function .Although exercise can help quit smoking and reduce relapses .However, exercise has many other fitness benefits when done regularly for the general population, as well as for smokers. Exercise has been shown to help with smoking cessation, which has been an important factor preventing many smokers, especially younger people, from quitting. Breathing exercises, especially diaphragm exercises improves lung function, lifestyle and health risk factors and thus the risk of developing many chronic diseases. Both aerobic interventions and exercise can reduce the incidence of many of the prevalent cancers initiated by smoking, such as lung cancer. This is important because lung cancer is the most common type of cancer worldwide, and cigarette smoking is responsible for up to 90% of lung cancer cases worldwide.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 23, 2025
CompletedFirst Posted
Study publicly available on registry
June 4, 2025
CompletedStudy Start
First participant enrolled
July 5, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 2, 2025
CompletedNovember 19, 2025
November 1, 2025
4 months
May 23, 2025
November 15, 2025
Conditions
Outcome Measures
Primary Outcomes (5)
FEV1/FVC ( % )
The ratio of the forced expiratory volume in the first one second to the forced vital capacity of the lungs. That can reflect pulmonary function , using portable spirometer ( SP 80B,China)
pre and post 4 weeks
FEV1 ( liters )
Forced expiratory volume in 1 second that can reflect pulmonary function , using portable spirometer ( SP 80B,China)
Pre and post 4 weeks
PEF ( liters / minute )
Peak expiratory flow (PEF), a key indicator of lung function,using portable spirometer ( SP 80B,China)
pre and post 4 weeks
FVC ( liters )
Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. Forced expiratory volume and forced vital capacity are lung function tests , using portable spirometer ( SP 80B , China )
Pre and post 4 weeks
Chest expansion ( centimeter )
A simple, noninvasive pulmonary function test used to assess chest wall mobility and, to a lesser extent, lung function , using tape measurement.
Pre and post 4 weeks
Secondary Outcomes (1)
Functional capacity
Pre and post 4 weeks
Study Arms (2)
Control group
ACTIVE COMPARATORperform exercises using aerobic exercises only
Experimental group
EXPERIMENTALperform diaphragmatic proprioceptive neuromuscular facilitation and aerobic exercise
Interventions
Control group will perform aerobic exercises only Experimental group will perform diaphragmatic proprioceptive neuromuscular facilitation in addition to aerobic exercises
Eligibility Criteria
You may qualify if:
- Adults aged 20-29 years.
- Subjects who have been smoking for 1 to 3 years.
- Subjects who not receiving medical treatment for respiratory diseases.
- Subjects who have clean family medical history.
You may not qualify if:
- Subjects who smoke cigars other than filtered cigarettes or tobacco pipes.
- Subjects with respiratory proplems.
- Participation in another clinical trial within the last 30 days.
- Endocrine and metabolic disorders (eg, hypothyroidism, hypercalcemia, diabetes mellitus, diabetes insipidus).
- Neurologic and psychiatric disorders (who can not understand the research project ).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mohamed Saied Zidan
Cairo, 11571, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant prof dr
Study Record Dates
First Submitted
May 23, 2025
First Posted
June 4, 2025
Study Start
July 5, 2025
Primary Completion
November 1, 2025
Study Completion
November 2, 2025
Last Updated
November 19, 2025
Record last verified: 2025-11